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Abstract
Alzheimer’s disease (AD) is the most common form of dementia and its preva-
lence is increasing. Recent developments in AD management provide improved
ways of supporting patients and their caregivers throughout the disease contin-
uum. Managing cardiovascular risk factors, maintaining an active lifestyle (with
regular physical, mental and social activity) and following a Mediterranean diet
appear to reduce AD risk and may slow cognitive decline. Pharmacologic ther-
apy for AD should be initiated upon diagnosis. All of the currently available
cholinesterase inhibitors (ChEIs; donepezil, galantamine, and rivastigmine) are
indicated for mild-to-moderate AD. Donepezil (10 and 23 mg/day) and
rivastigmine transdermal patch (13.3 mg/24 h) are indicated for moderate-to-
severe AD. Memantine, an N-methyl-D-aspartate receptor antagonist, is
approved for moderate-to-severe AD. ChEIs have been shown to improve cog-
nitive function, global clinical status and patients’ ability to perform activities
of daily living. There is also evidence for reduction in emergence of behavioral
symptoms with ChEI therapy. Treatment choice (e.g., oral vs. transdermal)
should be based on patient or caregiver preference, ease of use, tolerability, and
cost. Treatment should be individualized; patients can be switched from one
ChEI to another if the initial agent is poorly tolerated or ineffective. Memantine
may be introduced in moderate-to-severe disease stages. Clinicians will regularly
monitor symptoms and behaviors, manage comorbidities, assess function, edu-
cate and help caregivers access information and support, evaluate patients’ fit-
ness to drive or own firearms, and provide advice about the need for legal and
financial planning. Review of caregiver well-being and prompt referral for
support is vital.
Introduction
Alzheimer’s disease (AD) is the most common form of
dementia, accounting for 60–80% of cases.1 In the United
States, one in nine people aged ≥65 years has AD (two-
thirds of whom are women), and one person develops
AD every 67 sec.1 Alzheimer’s Disease International esti-
mates that the prevalence of AD will increase by 225% by
2050, affecting more than 115 million people globally,2
and more than 13.8 million people in the United States.1
AD is associated with initial memory loss, followed by
impairments in cognitive function, language, visuospatial
skills and executive function, coupled with behavioral
changes.3 Terminally, patients may become bedridden,
incontinent and unable to communicate.4 AD imposes an
intolerable burden on healthcare systems, society, patients
and their families, and is one of the leading contributors
to disability among elderly people.5 Most patients require
assistance with activities of daily living (ADL), and many
eventually require full-time care and supervision.2,4 Car-
ing for a patient with AD can be stressful, especially if the
patient displays neuropsychiatric symptoms, such as
irritability, dysphoria or delusions.6
Clinicians play a key role in the medical management
of AD, and provide recommendations and advice to
patients and families/caregivers on a broad range of
issues, including psychosocial problems, and legal and
financial resources.7 Specialists involved in AD diagnosis
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and management include neurologists, geriatricians and
geriatric psychiatrists.
Therapeutic nihilism (disbelief in the efficacy or clinical
value of a therapy) is a key issue in dementia manage-
ment, particularly among clinicians, due to negative asso-
ciations and stigma associated with this progressive
illness.8 These perceptions should be overcome as they
may delay diagnosis, referral, and treatment.8
This review provides recommendations on managing
AD based on current knowledge and available pharmaco-
logic agents. Support for patients, families, and caregivers
is also discussed, from early recognition to difficult deci-
sions around end-stage care. The goal of this approach is
to maximize quality of life throughout the course of this
complex disease. Data sources include pivotal clinical
studies of donepezil, galantamine, rivastigmine, meman-
tine, and medical foods identified using PubMed in 2014
and the relevant United States prescribing information.
English-language articles considered of relevance to pri-
mary care physicians in relation to AD, its diagnosis and
management, are included. Previous guidelines and man-
agement recommendations were reviewed. The recent
meta-analysis of brain health activities by Alzheimer’s
Disease International was a key document.9
General Brain Health and Wellness
Modifying risk factors for cognitive
dysfunction
There are potential risk factors for, or protective factors
against, cognitive dysfunction. It is reasonable to recom-
mend modifying these, based on the available evidence.
Recommendations for maintaining brain health in adults
with and without AD are summarized in Box 1.
Observational studies point to a protective role for cer-
tain nutrients and dietary patterns (Mediterranean diet).
However, data from randomized controlled trials have
been inconsistent. Whether factors such as cooking pro-
cesses and other dietary components explain these incon-
sistencies is uncertain. The potential mechanisms by
which certain nutrients may protect brain health also
remain to be established.10
Long-term studies on the relationship between physical
activity and the incidence of noncommunicable diseases
in general is limited. However, the few available studies
indicate that physical activity in healthy people is an
important factor preventing the development of cognitive
impairment and AD.11
Depression is associated with cognitive decline,12
supporting the management of depressive symptoms
in the elderly. Further, there is clinical rationale to
actively manage hyperlipidemia and diabetes.13 Untreated
hypertension is associated with rapid decline in cognitive
function in vulnerable individuals.14
A family history of AD is a risk factor for the disorder;
family members should be encouraged to adopt a brain-
healthy lifestyle.
Lifestyle considerations for patientswithAD
Despite evidence that omega-3 fatty acids slow cognitive
decline in the elderly, findings in patients with AD are
inconsistent.15–17 One trial reported benefits of omega-3
fatty acid and lipoic acid treatment on cognition and
ADL performance.16 However, due to small sample sizes,
further studies are required.16 Folic acid and vitamin B
supplements may help to preserve brain function.18 A
small, double-blind, randomized, controlled trial reported
that folic acid supplementation may improve response to
cholinesterase inhibitor (ChEI) therapy.19 Time to institu-
tionalization and daily living functioning have improved
following vitamin E supplementation.20,21 As with all
interventions, the benefit–risk ratio of supplements should
be considered. A recent meta-analysis concluded that high
blood levels of docosahexaenoic acid and eicosapentae-
noic acid are possibly associated with increased risks of
high-grade prostate cancer.22 These findings should be
interpreted with caution due to the multifactorial etiology
of prostate cancer, and the complex metabolism of long-
chain omega-3 fatty acids.22
Box 1. Recommendations for maintaining brain health in elderly
patients with and without AD
• Consider following a Mediterranean-style diet, with fish,
vegetables, legumes, fruit, cereals, unsaturated fatty acids (e.g.,
olive oil), and a limited amount of meat or dairy products.
• Consider taking supplements containing omega-3
(particularly docosahexaenoic acid), B-complex vitamins
(including B12, B6, folic acid), and vitamin E.
• Keep alcohol intake to a low-to-moderate level (e.g., one
glass of wine per day with dinner).
• Engage in regular physical activity.
• Maintain leisure and social activities – keep socially engaged.
• Continue or take up activities that help to stimulate the
brain, e.g., Tai Chi, dancing, puzzles.
• Become educated about AD and seek support from others
with AD, e.g., the Alzheimer’s Association, Alzheimer’s
Foundation of America, Keep Memory Alive, and other
community groups.
• Include music in daily life – listening to music, playing an
instrument, singing.
• Maintain regular sleep patterns.
• Manage stress – stop doing things if they are becoming too
stressful (e.g., volunteer work, answering the telephone),
keep to a regular daily schedule, include relaxing activities
(e.g., playing with pets, massage, and aromatherapy).
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Dementia symptoms are stressful for patients, care-
givers, and families.23–26 Patients who believe nothing can
be done about their illness are more likely to experience
depression,27 and clinicians should educate patients about
steps they can take to preserve function (Box 1). Learning
about AD and seeking support early in the disease course
can help reduce stress and improve coping and health-
related behaviors.28 Artistic pursuits may help maintain a
sense of identity and self-expression, improve aspects of
behavior, and enhance communication.29–31 Music ther-
apy reportedly improves language functions in patients
with dementia32 and symptoms of anxiety and depression
in patients with mild-to-moderate AD.33 Interactions with
pets may reduce agitation and anxiety in some patients
with dementia.34 Patients and caregivers can also reduce
stress by adjusting activities to suit the patient’s abilities,
and keeping to a regular daily routine that includes
relaxing activities.35
Clinicians should urge patients with AD to participate
in leisure activities, where possible, preserving function
and quality of life.23,25,36 Cognitive training may improve
function, so patients should be encouraged to learn new
skills or hobbies and undertake activities that stimulate
mental activity.12,37 Social interactions may be difficult for
patients with AD, and they may withdraw due to self-
consciousness, depression, or apathy.23,25 Participation in
specialized adult day programs for patients with dementia
may enhance the benefits of drug therapy and improve
sleep quality, by keeping the patient engaged and reduc-
ing inactivity.38 Specialized memory rehabilitation pro-
grams for patients with AD have also proven valuable,39
but are not widely available.
Diagnosis
In clinical trials, the Diagnostic and Statistical Manual of
Mental Disorders, 4th edition (DSM-IV) criteria are com-
monly used to diagnose dementia of the Alzheimer’s
type.40 Recently, an updated version, DSM-5, was pub-
lished; key updates are the change in dementia to the
newly named entity “major neurocognitive disorder
(NCD)”, and recognition of a less severe level of cognitive
impairment, termed “mild NCD”.41
The most recent diagnostic guidelines from the
National Institute on Aging and Alzheimer’s Association
define three stages of AD:42
• Preclinical phase: neuropathologic changes occur, no
overt (or only subtle) symptoms.
• Phase of mild cognitive impairment: symptoms become
apparent; ADL are preserved; the patient does not have
dementia.
• Dementia phase: ADL are impaired.
There may be preclinical neurologic changes in the
form of cerebrospinal fluid or amyloid imaging biomar-
kers.43 However, AD diagnosis is principally based on
clinical criteria (Fig. 1);44,45 biomarkers can be used to
define AD as the probable underlying cause of cognitive
impairment, but are not strictly necessary for diagno-
sis.42,45 The accuracy of diagnosis is enhanced by integra-
tion of biomarkers. Table 1 outlines the recommended
diagnostic steps.46
Pharmacotherapy
There are a number of Food and Drug Administration
(FDA)-approved pharmacotherapies for AD (Table 2).
These may improve symptoms or delay decline; none
impact the underlying neurodegenerative process.47 It is
important for patients and their caregivers to understand
this, so they can make informed treatment decisions and
have realistic expectations regarding the impact of
treatment.48
ChEIs
Three ChEIs (donepezil [Aricept; Eisai Inc., Woodcliff
Lake, New Jersey], galantamine [Razadyne; Janssen Phar-
maceuticals Inc, Titusville, New Jersey] and rivastigmine
[Exelon capsules and Exelon Patch; Novartis Pharma-
ceuticals Corporation, East Hanover, New Jersey]) are
indicated for mild-to-moderate AD in the United States;
donepezil and rivastigmine transdermal patch are also
indicated for severe AD.49–52 All three ChEIs are approved
in oral formulations;49–51 rivastigmine is the only ChEI
also approved for delivery via a transdermal patch.52
Approval of high-dose 23 mg/day donepezil for moder-
ate-to-severe AD was based on a randomized clinical trial
that demonstrated greater cognitive efficacy versus the
standard dose (10 mg/day).53 The high-dose (13.3 mg/
24 h) rivastigmine patch was approved for mild-to-mod-
erate and severe AD, based on positive findings in the
OPTIMA (OPtimising Transdermal Exelon In Mild-to-
moderate Alzheimer’s disease) and ACTION (ACTivities
of daily living and cognitION) studies, respectively.54,55
All three ChEIs have demonstrated clinical benefits on
cognitive function, global clinical status,54–57 and perfor-
mance of ADL.54–56,58 There are no proven clinically
meaningful differences between the agents in terms of
efficacy.56,57,59 Efficacy and tolerability associated with
ChEIs are dose dependent,60 so while high doses may be
efficacious, adverse events (AEs) can be dose limiting.
The agents have similar tolerability profiles, with nausea,
vomiting, and diarrhea being the most common AEs.56
Gastrointestinal (GI) AEs typically arise due to peaks in
plasma drug concentrations.61 Strategies that reduce the
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Is dementia present? i.e. cognitive and behavioral (neuropsychiatric) symptoms that:
1.  Interfere with the ability to function at work or at usual activities; and
2.  Represent a decline from previous levels of functioning and performing; and
3.  Are not explained by delirium or major psychiatric disorder.
•   Cognitive impairment is detected and diagnosed through a combination of (1) history-taking 
    from patient and a knowledgeable informant and (2) an objective cognitive assessment
•   The cognitive or behavioral impairment involves ≥2 of the following domains:
•   Impaired ability to acquire and remember new information
•   Impaired reasoning and handling of complex tasks, poor judgement
•   Impaired visuospatial abilities
•   Impaired language functions
•   Changes in personality, behavior, or comportment
Probable AD
1.  Meets criteria for dementia
2.  Insidious onset
3.  Clear-cut history of 
     worsening cognition by 
     report or observation
4.  Cognitive deficits on history 
     and examination are:
     a.  Amnestic (impairment of 
          learning or recall of 
          recently learned 
information and ≥1 other 
cognitive domain)
     b.  Non-amnestic (language, 
          visuospatial or executive 
          functions are most 
          prominent, but deficits in 
          other cognitive domains 
          are also present) 
5.  No evidence of substantial 
     concomitant cerebrovascular 
     disease, Lewy body 
     dementia, frontotemporal 
     dementia, primary 
     progressive aphasia, 
     neurological disease or drug 
     toxicity
                                Possible AD Unlikely to be AD
Meets core clinical criteria 
for dementia but has:
1.  Atypical clinical course, 
     e.g. sudden onset or there 
     is insufficient historical 
     detail or objective cognitive 
     documentation of 
     progressive decline
2.  Evidence of etiologically 
     mixed presentation, 
     e.g. concomitant 
     cerebrovascular disease, 
     features of Lewy body 
     dementia, evidence of other 
     neurological disease or 
     potential drug toxicity with 
     substantial effect on 
     cognition
1.  Does not meet clinical 
     criteria for AD dementia 
2.  Regardless of meeting 
     clinical criteria for probable 
     or possible AD dementia, 
     there is sufficient evidence 
     for an alternative diagnosis 
     e.g. HIV dementia, or 
     dementia of Huntington’s 
     disease
Still in doubt?
Refer for imaging (MRI, PET) or CSF analysis to assess biomarkers
Is it AD?
Figure 1. Diagnostic criteria for AD.45 Permission to reproduce text used in this figure was kindly provided by Elsevier Limited.
AD, Alzheimer’s disease; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; PET, positron emission tomography.
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dosing frequency, lower peak plasma concentrations,
and reduce the rate at which peak concentrations are
reached may improve tolerability.62 A sustained-release
formulation of donepezil was developed to provide access
to high therapeutic doses, while avoiding the rapid rises
in peak drug plasma concentrations.53 Donepezil 23 mg/
day is associated with greater cognitive benefits in moder-
ate-to-severe AD than donepezil 10 mg/day IR; however,
there is an dose-related increase in AEs.53
A pharmacokinetic analysis predicted lower peaks in
plasma drug concentrations, but a similar area under the
curve, with extended-release (ER) galantamine compared
with the IR formulation.63 During a clinical study, both
once-daily galantamine ER and twice-daily galantamine
IR (flexible dosing of 16 or 24 mg/day) demonstrated
superiority to placebo on cognition in patients with mild-
to-moderate AD, with a similar incidence of AEs observed
in all three groups.64
By providing sustained delivery over a 24-h period,
transdermal delivery may improve GI tolerability and per-
mit easier access to high-dose efficacy compared with oral
dosing.62 Relative to 6 mg twice-daily oral rivastigmine,
9.5 mg/24 h rivastigmine transdermal patch was associ-
ated with comparable efficacy and two-thirds fewer GI
AEs.65 Rivastigmine patch treatment is initiated with the
4.6 mg/24 h dose, with up-titration to the minimum
effective dose of 9.5 mg/24 h patch after at least 4 weeks,
assuming good tolerability.52 After an additional
4 weeks, if well-tolerated, the dose may be increased to
13.3 mg/24 h patch.52 Continued use of the 4.6 mg/24 h
dose can be considered in patients weighing less than
50 kg with tolerability concerns, or patients with mild-to-
moderate hepatic impairment.52
Transdermal delivery may be associated with applica-
tion site reactions in some patients; the occurrence can be
minimized by following the recommendations in the riv-
astigmine patch United States prescribing information.52
These include: rotating the application site; applying the
patch only to clean, dry, hairless skin that is free of
redness, irritation, cuts, or burns; and ensuring the skin
is free of creams, lotions, or powders prior to patch
application.52
After initiating ChEI treatment, patients should be
assessed after 2–4 weeks for the development of AEs,7
and after 3–6 months for effects on cognitive function
and other behaviors/abilities.7 ChEI doses should be
Table 1. Steps in the diagnosis and assessment of a patient with suspected AD in primary care.46
Step Purpose Tools/information required
Step 1: Prediagnostic tests Identify risks for neurocognitive disorders • Risk factor assessment
• Medical history
• Laboratory tests to identify risk factors and define
comorbidities and early warning signs of preclinical dementia
Step 2: Assess performance Cognitive assessment • Cognitive tests e.g., MMSE,126 Mini-cog,127 MoCA,128
SIB-8129
• Informant-rated tools e.g., AD8130
Step 3: Assess daily
functioning
Determine level of independence and
degree of disability
• Daily function assessment tool e.g., ADCS–ADL131
Step 4: Assess behavioral
symptoms
Determine presence and degree
of behavioral symptoms
• Behavioral assessment tool e.g., NPI-Q132
• Assess for other potential causes of behaviors
(e.g., drug toxicity, medical or psychiatric comorbidity)
Step 5: Identify caregiver
and assess needs
Identify primary caregiver and assess
adequacy of family and other support
systems
• Identify caregiver(s) and establish collaboration
• Assess health of primary caregiver
• Refer to psychologist, social worker, or other healthcare
resources as needed
Other considerations Identify cultural differences, language,
and literacy level of patient and caregiver
• Recognize differences in illness interpretations and
caregiving patterns between cultures
• Be aware of preferred language
• Recognize that paper-and-pencil tests and forms may
not work well if patient or caregiver has literacy/language
barriers
AD, Alzheimer’s disease; AD8, 8-item Ascertain Dementia tool; ADCS-ADL, Alzheimer’s Disease Cooperative Study–Activities of Daily Living scale;
Mini-cog, Mini Cognitive Assessment Instrument; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; NPI-Q,
Neuropsychiatric Inventory Questionnaire; SIB-8, Severe Impairment Battery (8-item).
Reproduced by permission of the American Board of Family Medicine.
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up-titrated according to the prescribing information
(Table 2).49–52 Regular follow-up appointments should be
established to assess disease progression. Patients should
be switched to another ChEI if they develop intolerable
or nontransient AEs, if they do not respond to the initial
agent (i.e., continued deterioration at pretreatment rate),7
or if caregiver or patient preferences change. The princi-
ple of switching is to transition the patient from one
ChEI to another in an attempt to improve clinical out-
comes. Switching should follow the recommendations
outlined in the relevant prescribing information.49–52
NMDA receptor antagonist
Memantine (Namenda; Forest Pharmaceuticals Inc.,
St Louis, Missouri) is an N-methyl-D-aspartate (NMDA)
receptor antagonist indicated for moderate-to-severe AD
(Table 2).66,67 Clinical studies have demonstrated efficacy
of memantine (20 mg/day) versus placebo on cognition,
global function, and ADL performance.68,69 A high-dose
(28 mg/day) once-daily ER formulation has demonstrated
cognitive efficacy, and an acceptable tolerability profile,
compared with placebo in patients with moderate-to-
severe AD receiving ChEIs.70 Memantine can be used as
monotherapy71 or in combination with a ChEI.7,47 Com-
bining two agents with different mechanisms of action,
may improve efficacy relative to single-agent therapy, and
the use of memantine with oral ChEIs may ameliorate
ChEI-related GI AEs.47
Medical foods
Several medical foods are available in the United States
for management of AD and/or cognitive impairment,
including:
• Caprylidene (Axona; Accera Inc., Broomfield, Califor-
nia), a proprietary formulation of medium-chain trigly-
cerides, intended for dietary management of mild-to-
moderate AD.72
• Cerefolin NAC (PAMLAB, LLC, Covington, Louisi-
ana), a combination of folic acid, vitamin B12, and N-
acetylcysteine, intended for dietary management of mild
cognitive impairment.73
• Vayacog (VAYA Pharma Inc., Greenville, South Caro-
lina), a combination of phosphatidylserine, docosahexa-
enoic acid, and eicosapentaenoic acid, intended for
dietary management of lipid imbalances associated with
early memory impairment.74
Noncarriers of the apolipoprotein e4 allele have shown
significant improvements in cognitive function with ca-
prylidene.75 Currently, there is limited published evidence
to support using folic acid, vitamin B12, and N-acetylcys-
teine,76 except in the setting of hyperhomocysteinemia.
However, in older adults receiving folic acid supplementa-
tion for 3 years, plasma homocysteine levels were reduced
and memory function improved compared with
placebo.77
A 15-week, randomized, double-blind study reported
that phosphatidylserine-containing omega-3 fatty acids
improved cognitive performance in elderly with memory
complaints without dementia, although further studies
are required to confirm these findings.78
Souvenaid (Nutricia Advanced Medical Nutrition,
Schiphol, The Netherlands) a combination of omega-3
fatty acids, uridine, choline, vitamins C, E, B6, and B12,
selenium, and folic acid is not yet available in the United
States. Souvenaid is available in Europe (Food for Spe-
cial Medical Purpose) as a dietary means of supporting
synaptic integrity. In clinical trials of patients with mild
AD, this combination demonstrated a significant
improvement in delayed verbal memory,79,80 but not glo-
bal cognition,79 or performance of ADL.81
No single agent or combination will suit every patient,
so clinicians should construct a comprehensive, inte-
grated, multifaceted treatment plan that reflects the pref-
erences of the patient and caregiver, and the most recent
scientific guidance. Clinicians should be prepared to reas-
sess their approach to achieve optimal therapeutic bene-
fit/outcomes. The optimal duration of ChEI treatment
has not been established, but patients in clinical trials
have shown benefit for up to 4 years,82 so continuing
treatment as long as patients tolerate the medication and
families support treatment is reasonable. Maintaining
open discussions with the family on disease progression
and treatment outcomes may guide the clinician regard-
ing whether or not to maintain treatment, and help the
family to prepare for the eventual need for long-term
residential placement.
Managing Comorbidities
In one study of 679 patients with AD in the United
States, 61% had ≥3 medical comorbidities, and the num-
ber increased with advancing dementia severity.83 After
controlling for other variables, higher medical comorbidi-
ty was associated with worse cognitive function and
poorer self-care.83 Other data show that patients with AD
are 55% more likely to be admitted to hospital than
people without AD.84 Common medical comorbidities in
patients with AD include cardiovascular disease, thyroid
dysfunction, sleep apnea, osteoporosis, glaucoma, cancer,
falls, depression, infections, anorexia, rheumatoid condi-
tions, and incontinence.85,86 One key treatable comorbid-
ity is sleep apnea. In addition to being a risk factor for
hypertension, stroke, and mortality,87,88 sleep apnea has
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Table 2. (A) Food and Drug Administration-approved AD therapies and (B) medical foods.
Mechanism
Approved/
intended
indication
Administration
Route Dosing Frequency
(A) Pharmacologic agents
Donepezil (Aricept)49 ChEI Mild-to-
moderate
AD
• Moderate-
to-severe
AD
PO (tablet) Titration:
• Initiate 5 mg/day
• May increase to 10 mg/day after
4–6 weeks
• Severe AD: may increase to 23 mg/day
after additional 3 months (minimum)
Maintenance:
• Mild-to-moderate AD: 5 or 10 mg/day
• Moderate-to-severe AD: 10 or
23 mg/day
Once daily
Galantamine (Razadyne)50 ChEI Mild-to-
moderate
AD
PO (tablet/oral
solution)
Titration :
• Initiate: 8 mg/day
• Increase to 16 mg/day after 4 weeks
(minimum)
• May increase to 24 mg/day after
additional 4 weeks (minimum)
Maintenance:
• 16 or 24 mg/day
Twice
daily,
with
food
Galantamine ER
(Razadyne ER)50
ChEI Mild-to-
moderate
AD
PO (capsule) Titration:
• Initiate: 8 mg/day
• Increase to 16 mg/day after 4 weeks
(minimum)
• May increase to 24 mg/day after
additional 4 weeks (minimum)
Maintenance:
• 16 or 24 mg/day
Once
daily, in
morning,
with
food
Rivastigmine (Exelon)51 ChEI Mild-to-
moderate
AD
• Mild-to-
moderate
PDD
PO (capsules/
oral
solution)
Titration:
• Initiate: 3 mg/day
• If tolerated, may increase to 6 mg/day,
and further to 9 and 12 mg/day after
2 weeks (minimum) at previous dose
(4 weeks for PDD)
Maintenance:
• Mild-to-moderate AD: 6–12 mg/day
• Mild-to-moderate PDD: 3–12 mg/day
Twice
daily
Rivastigmine patch
(Exelon Patch)52
ChEI Mild-to-
moderate
AD
• Severe AD
• Mild-to-
moderate
PDD
TD patch Titration:
• Initiate: 4.6 mg/24 h
• After 4 weeks (minimum), if tolerated,
increase to 9.5 mg/24 h
• May increase to 13.3 mg/24 h after
additional 4 weeks (minimum)
Maintenance:
• Mild-to-moderate AD: 9.5 or
13.3 mg/24 h
• Severe AD: 13.3 mg/24 h
Apply new
patch
once
every
24 h
(Continued)
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been reported as a significant risk for dementia in older
women, nearly doubling the risk for mild cognitive
impairment and dementia over 5 years.89 It is therefore
important for clinicians to evaluate the presence of sleep
disordered breathing as another modifiable risk.
It is important for clinicians to manage conditions co-
morbid to AD (Box 2). This can limit cognitive and func-
tional decline,85 and reduce the risk of hospital
admission, which can be disorienting, distressing, and
lead to medication discontinuation. Moreover, medical
illness and pain are common triggers for agitation or
aggression in patients with AD,47 so early recognition and
treatment of comorbid medical conditions can limit neu-
ropsychiatric and behavioral symptoms.
Neuropsychiatric symptoms are a key component of
AD, affecting almost all patients over the disease course.90
Studies suggest that more than 90% of patients with AD
show behavioral or neuropsychiatric symptoms, including
depression, agitation, anxiety, psychosis, hallucinations,
apathy, eating disorders, disinhibition, and sleep distur-
Table 2. Continued.
Mechanism
Approved/
intended
indication
Administration
Route Dosing Frequency
• Mild-to-moderate PDD: 9.5 or
13.3 mg/24 h
Memantine (Namenda)66 NMDA receptor
antagonist
Moderate-
to-severe
AD
PO (tablet/oral
solution)
Titration:
• Initiate 5 mg/day
• Increase to 10 mg/day, and further to
15 and 20 mg/day after 1 week (mini-
mum) at previous dose
Maintenance:
• 20 mg/day
Twice
daily
Memantine (Namenda) XR67 NMDA receptor
antagonist
Moderate-
to-severe
AD
PO (capsules) Titration:
• Initiate: 7 mg/day
• Increase dose (14, 21, and 28 mg/day)
after 1 week (minimum) on previous dose
Maintenance:
• 28 mg/day
Once daily
(B) Medical foods
Caprylidene (Axona)72 Medical food –
nutritionally
supports brain
metabolism
Mild-to-
moderate
AD
PO (powder
to be added
to 4–8 oz of
liquid)
Titration:
• 8–10 g/day for 2 days
• Increase dose by 8–10 g every other
day, as tolerated, up to a maximum of
40 g/day
Maintenance:
• 40 g/day
Once daily
after
food
L-methylfolate/methylcobalamin/
N-acetylcysteine
(CerefolinNAC, Triveen-CF
NAC)73
Medical food –
supports the
brain’s
metabolic
balance
Mild or
moderate
cognitive
impairment
PO (caplet) 1 caplet/day Once daily
Phosphatidylserine/
docosahexaenoic acid/
eicosapentaenoic acid
(Vayacog)
Medical food –
supports
management of
lipid imbalances
Early
memory
impairment
PO (capsule) 1 capsule/day Once daily
Omega-3 fatty acids, uridine,
choline, vitamins C, E, B6,
and B12, selenium, and folic
acid (Souvenaid)
Medical food –
supports
synaptic
integrity
Early AD PO (liquid) 1 bottle (125 mL) per day Once daily
In contrast to FDA-approved drugs, no premarket review process exists for medical foods: data supporting their effectiveness (if such data exist)
have not undergone the same rigorous scientific scrutiny as approved drugs. AD, Alzheimer’s disease; ChEI, cholinesterase inhibitor; ER, extended
release; NMDA, N-methyl-D-aspartate; PDD, Parkinson’s disease dementia; PO, per os (oral administration); TD, transdermal.
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bances.91–93 The first step in management is to rule out
potential medical and/or somatic causes, for example,
lower urinary tract infection,7,86,94 and recommend non-
pharmacologic interventions (Table 3).7 ChEIs or me-
mantine may delay or relieve symptoms,7,86,95 but some
patients may require targeted pharmacotherapy, such as
antipsychotics or antidepressants. Although antidepressant
agents may be efficacious in treating depression in
patients with AD, the supporting evidence is limited, and
no agent has been approved specifically for depression or
psychosis of AD.96,97 A cross-sectional study reported that
treatment of neuropsychiatric symptoms in elderly
patients with dementia residing in care homes is generally
not syndrome specific, and included use of neuroleptics
and other substances not indicated for dementia.98 Anti-
psychotic use has been associated with an increased risk
of death due to pneumonia in elderly patients with
dementia,94 highlighting the importance of investigating
the underlying cause of behavioral symptoms prior to
prescribing treatment.
Patients with AD exhibiting agitation and other neuro-
psychiatric symptoms often receive anticonvulsants, such
as divalproex, as a second-line treatment.99,100 However,
data from controlled clinical studies suggest divalproex
accelerated brain atrophy, and did not benefit patients
with moderate AD in terms of neuropsychiatric symp-
toms, functional abilities, and cognition.101,102
There is significant potential for polypharmacy in
patients with AD.103 Clinicians should be aware of poten-
tial drug interactions when introducing new medications
and of difficulties in maintaining compliance/adherence
with complex drug regimens.103 Attempts should be made
to simplify the medication regimen, for example, use of
alternate modes of delivery that are more user friendly.103
Societal and Financial Impact
Residential care is a major contributor to the financial
impact of AD. In several studies ChEI treatment was asso-
ciated with a delay in time to nursing home placement,104
an effect that is reportedly dose dependent.105 Similarly,
evidence suggests cost-savings with memantine compared
with nonpharmacological treatment in moderately severe-
to-severe AD,106 as well as some benefit for combined
ChEI/memantine therapy based on health-care data from
France.107
Nonpharmaceutical interventions in the management
of behavioral symptoms and mood disorders have also
been linked to improved cognitive and functional ability,
enhanced patient and caregiver quality of life and delayed
institutionalization.7
Other Considerations
Clinicians responsible for patients with AD should pay
attention to several areas that may impact well-being, and
not only medication (Box 3).
Box 2. Management of comorbidities
• Assess regularly for medical and neuropsychiatric comorbidities.
• Manage comorbidities, particularly cardiovascular risk factors,
with lifestyle recommendations and medications to reduce
risk of cognitive decline.
• Investigate potential medical, somatic, or medication-related
reasons for any new change in function or behaviors.
• Promptly treat acute medical illnesses to reduce the risk of
hospital admission.
• Offer caregiver education and support to help manage
neuropsychiatric or behavioral symptoms (Table 3).
• Initiate psychoactive medication as necessary, balancing the
benefits and risks, and document a discussion with the
patient and/or family members in the medical record.
• Be aware of adverse impact of polypharmacy and potential
for drug–drug interactions.
• Encourage adherence – simplify medication regimen, where
possible.
Table 3. Nonpharmacologic approaches to manage common
behavioral symptoms and mood disorders.7
Behavioral symptom Nonpharmacologic intervention
Apathy Stimulation/activities
• Simple tasks
Sleep disturbances Take steps to maintain regular,
good quality sleep
• Stimulation during the day
(especially adult day services)
• Reduction in excessive
stimulation/noise in the evening
Irritability/agitation Break down tasks into simple steps
• Redirection
Wandering Visual cues
• Exercise
• Safe places to wander
• Enrollment in wandering
assistance schemes
Mood disorders Exercise
Psychotic disorders Reassurance
• Distraction rather than confrontation
• Removal of potential sources
of confusion, e.g., mirrors
Eating/appetite disorders Offering simple, finger foods
• Removal of distractions from dining area
• Soothing music
Permission to reproduce this table was kindly provided by the
Alzheimer’s Disease Program, California Department of Public Health.
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Safety
Keeping the person with AD safe is important, to prevent
injuries, maximize function, minimize stress and agita-
tion, and reduce caregiver burden.7 A home assessment
may be useful to identify hazards that could increase the
risk of falls. Patients with AD may no longer remember
how to use appliances correctly, identify toxic substances,
or handle sharp objects, so caregivers should ensure that
potentially harmful objects are removed.7 The Alzheimer’s
Association, Alzheimer Foundation of America, and other
advocacy groups have resources on how to assess and
manage patient safety in the home.108
Approximately 60% of US households that have a family
member with dementia have a gun.109 Few laws regulate
gun ownership in relation to age or cognitive function.110
Since patients with dementia may develop aggressive
behaviors toward themselves and others as the disease pro-
gresses,111 firearms pose a risk of serious injury.110 When it
comes to gun ownership, clinicians need to balance the
patient’s right to autonomy against the need for safety.7,112
Patients with AD will have to stop driving when their
limitations make it unsafe. Discussing this possibility early
in the disease course can help planning.113 Clinicians
should be familiar with their state’s regulations regarding
minimum cognitive requirements for licensure, and legal
requirements for reporting the diagnosis. The American
Occupational Therapy Association website (http://www.ao-
ta.org) identifies resources for people with AD and their
families, including a national database of driving specialists,
who can evaluate and offer strategies to reduce driving risk.
Ongoing follow-up
Clinicians need to regularly assess the patient for changes
in daily functioning, cognitive status, comorbidities, behav-
ioral symptoms, medication requirements, and care needs;
any sudden changes require attention.7 Weight loss occurs
in ~40% of patients with AD.114 Patients showing signs of
weight loss should be offered nutritional supplementation
and advice on increasing daily calorie intake. Dosing modi-
fications may also be appropriate for these patients.
Abuse
Clinicians are well placed to identify potential patient
abuse and neglect, or signs of overwhelming stress and
abuse in caregivers.7 It is important to recognize that
abuse may be exerted by the patient on the caregiver or
vice versa.7 Effective management of aggressive symptoms
or psychiatric comorbidities is essential, as is timely
referral to support services. Across the United States, a
number of elder abuse multidisciplinary teams exist,
which provide expert consultation to service providers,
and identify service gaps and systems problems when
managing cases of abuse.115
Residential care and legal aspects
The most common reasons for patients to move to
residential care are the need for more skilled care than
the caregiver can provide, the caregiver’s health, and
the patient’s dementia-related behaviors.116 Discussing the
potential future need for residential care early in the
disease course, and identifying the threshold for such
decisions, can ease the process. Clinicians should advise
patients and their caregivers to plan for when the patient
will have diminished capacity, and seek legal advice to
put in place the necessary powers of attorney, as well as
documentation around end-of-life preferences, such as
wills and advance directives/living wills.7
Caregiver well-being
The importance of shaping policy and practice to support
the caregiver cannot be overemphasized.117 Demands on
Box 3. Checklist for clinicians caring for patients with AD
Health
• Have you provided the patient/caregiver with nutritional
advice?120
• If using a transdermal patch, have you provided the patient/
caregiver with guidance on best patch use, including skin
care?52
• Are you regularly assessing your patient’s clinical and
functional state?
Safety
• Have you or has someone else (caregiver, social worker)
assessed the safety of the patient’s home?113
• Have you asked your patient and their caregiver(s) about
firearms in the home?113
• Have you talked to your patient and their caregiver(s) about
the likely need to stop driving?121
Legal considerations
• Have you advised your patient and their caregiver(s) to seek
legal advice with regard to planning for future incapacity?122
• Are you aware of the state requirements regarding medical
fitness to drive for patients with AD?121
• Are you aware of your legal obligations/appropriate steps to
take if you suspect abuse/neglect in the patient or
caregiver?123
Support
• Are you regularly assessing how the caregiver is coping and
the caregiver’s physical health?124
• Have you provided the caregiver with information on how to
access local support services?125
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caregivers increase as the disease progresses, and may
include managing bathing, dressing, feeding, and toilet-
ing.86 Caregivers must cope with sometimes challenging
behaviors while dealing with the emotional impact of the
changes to their relationship with the patient. They are
essential in providing information to healthcare profes-
sionals about symptomatic and functional changes in the
patient.118 Clinicians should pay careful attention to the
physical and psychological health of caregivers.119 Educa-
tion, support, counseling, respite care, and referral to
other services may be required. Involving a social worker
early in the course of the disease can help caregivers gain
Diagnose  (Figure 1 and Table  2)
Evaluate cognition, function and behavior
Considerations throughout the disease 
course
Refer to Box 1, Box 2, Box 3 and Table 3
Moderate-to-Severe AD
Initiate ChEI treatment 
at following doses:
Donepezil 5 mg once-daily
Rivastigmine (patch) 4.6 mg/24 h
Consider a combination 
of ChEI + memantine
Mild-to-moderate AD
Initiate ChEI treatment at following doses:
Donepezil 5 mg once-daily
Galantamine  (oral tablets/solution)
4 mg twice-daily
Galantamine (ER capsules)
8 mg once-daily
Rivastigmine (oral) 1.5 mg twice-daily
Rivastigmine (patch) 4.6 mg/24 h
Monitor
Every 6 months or in response 
to sudden change
Treat BPSD as required
Patient 
progresses
Consider higher 
dose (if 
available) or 
switch to a 
different ChEI
Re-evaluate
and titrate dose in accordance with relevant 
PI, if tolerability permits
Consider medical food(s), such as caprilidine, 
once ChEI treatment stable
Re-evaluate 
and titrate dose in accordance with relevant 
PI, if tolerability permits
Monitor
Every 6 months or in response 
to sudden change
Treat BPSD as required
Discontinue therapy
When patients advance to loss of all 
cognitive and functional abilities
Considering treating BPSD 
as required, 
with family/caregiver input
Patient 
develops 
AEs
Consider 
switch to a 
different ChEI
Identify caregiver
Provide education and support
Assess physical and mental health
Consider referral for support groups/ 
social worker
Figure 2. Treatment and management of AD.47 Permission to reproduce this figure was kindly granted by Physician’s Weekly. AD, Alzheimer’s
disease; BPSD, behavioral and psychological symptoms of dementia; ChEI, cholinesterase inhibitor; ER, extended release; PI, prescribing
information.
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access to local support services and provide advice around
financial assistance.7
Summary
AD is one of the most challenging chronic conditions to
manage. Treatment must be individualized for the symp-
toms, functional status, comorbidities, behaviors, and the
psychosocial situation of each patient, and requires regu-
lar reassessments for changes in the patient’s and care-
giver’s medical, mental, and psychological states. Figure 2
shows an algorithm for how to manage AD in primary
care. Early diagnosis, referral to specialists, and treatment
initiation are key; as are understanding and conveying
realistic expectations of treatment. Patients respond indi-
vidually to different interventions, so clinicians should be
willing to change medications to maximize patient and
caregiver quality of life, and to engage the assistance of
other healthcare professionals (e.g., geriatricians, neurolo-
gists, psychiatrists, psychologists, physical or occupational
therapists, social workers). It should be emphasized to
patients and caregivers that, while the progressive course
of AD cannot be reversed, lifestyle changes and medica-
tion can delay the progression of cognitive and functional
symptoms of AD and maximize quality of life.
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